{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T17:13:44Z","timestamp":1790615624232,"version":"4.1.0"},"reference-count":108,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T00:00:00Z","timestamp":1672790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T00:00:00Z","timestamp":1672790400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Immunol Res"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1007\/s12026-022-09356-y","type":"journal-article","created":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T13:32:50Z","timestamp":1672839170000},"page":"328-355","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Anti-IL23 biologic therapies in the treatment of psoriasis: real-world experience versus clinical trials data"],"prefix":"10.1007","volume":"71","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4658-7391","authenticated-orcid":false,"given":"Angelo","family":"Ruggiero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Megna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Fabbrocini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia Sofia","family":"Ocampo-Garza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,4]]},"reference":[{"issue":"5","key":"9356_CR1","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.3390\/jcm10051031","volume":"10","author":"A Ruggiero","year":"2021","unstructured":"Ruggiero A, Fabbrocini G, Cacciapuoti S, Cinelli E, Gallo L, Megna M. Ocular Manifestations in Psoriasis Screening (OcMaPS) Questionnaire: a useful tool to reveal misdiagnosed ocular involvement in psoriasis. J Clin Med. 2021;10(5):1031.","journal-title":"J Clin Med"},{"key":"9356_CR2","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1111\/bjd.12230","volume":"168","author":"K Danielsen","year":"2013","unstructured":"Danielsen K, Olsen AO, Wilsgaard T, Furberg AS. Is the prevalence of psoriasis increasing? A 30\u2013year follow-up of a population\u2013based cohort. Br J Dermatol. 2013;168:1303\u201310.","journal-title":"Br J Dermatol"},{"issue":"6","key":"9356_CR3","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1080\/1744666X.2020.1776116","volume":"16","author":"M Megna","year":"2020","unstructured":"Megna M, Cinelli E, Camela E, Fabbrocini G. Calcipotriol\/betamethasone dipropionate formulations for psoriasis: an overview of the options and efficacy data. Expert Rev Clin Immunol. 2020;16(6):599\u2013620. https:\/\/doi.org\/10.1080\/1744666X.2020.1776116.","journal-title":"Expert Rev Clin Immunol"},{"issue":"1","key":"9356_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40257-017-0328-3","volume":"19","author":"M Amin","year":"2018","unstructured":"Amin M, No DJ, Egeberg A, Wu JJ. Choosing first-line biologic treatment for moderate-to-severe psoriasis: what does the evidence say? Am J Clin Dermatol. 2018;19(1):1\u201313. https:\/\/doi.org\/10.1007\/s40257-017-0328-3.","journal-title":"Am J Clin Dermatol"},{"key":"9356_CR5","unstructured":"https:\/\/www.psoriasis.org\/remicade\/ Accessed 22\u00a0\u00a0Jan\u00a02021."},{"key":"9356_CR6","unstructured":"https:\/\/www.psoriasis.org\/skyrizi\/\u00a0Accessed 22\u00a0Jan\u00a02021."},{"key":"9356_CR7","unstructured":"https:\/\/www.drugwatch.com\/fda\/approval-process\/#:~:text=device%20approval%20process.-,FDA%20Drug%2DApproval%20Process,FDA%20post%2Dmarket%20safety%20monitoring. Accessed 22 Jan\u00a02021."},{"key":"9356_CR8","unstructured":"Janssen Biotech Inc. Janssen announces U.S. FDA approval of TREMFYA(T) (guselkumab) for the treatment of moderate to severe plaque psoriasis [media release]. 13 July 2017.\u00a0http:\/\/www.janssen.com. Accessed 22 Jan\u00a02021."},{"issue":"8","key":"9356_CR9","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1007\/s40265-019-01136-7","volume":"79","author":"K McKeage","year":"2019","unstructured":"McKeage K, Duggan S. Risankizumab: first global approval. Drugs. 2019;79(8):893\u2013900. https:\/\/doi.org\/10.1007\/s40265-019-01136-7.","journal-title":"Drugs"},{"issue":"2","key":"9356_CR10","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1056\/NEJMoa1501646","volume":"373","author":"KB Gordon","year":"2015","unstructured":"Gordon KB, Duffin KC, Bissonnette R, Prinz JC, Wasfi Y, Li S, Shen YK, Szapary P, Randazzo B, Reich K. A phase 2 trial of guselkumab versus adalimumab for plaque psoriasis. N Engl J Med. 2015;373(2):136\u201344. https:\/\/doi.org\/10.1056\/NEJMoa1501646.","journal-title":"N Engl J Med"},{"issue":"3","key":"9356_CR11","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.jaad.2016.11.041","volume":"76","author":"A Blauvelt","year":"2017","unstructured":"Blauvelt A, Papp KA, Griffiths CE, Randazzo B, Wasfi Y, Shen YK, Li S, Kimball AB. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol. 2017;76(3):405\u201317. https:\/\/doi.org\/10.1016\/j.jaad.2016.11.041.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"9356_CR12","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.jaad.2016.11.042","volume":"76","author":"K Reich","year":"2017","unstructured":"Reich K, Armstrong AW, Foley P, Song M, Wasfi Y, Randazzo B, Li S, Shen YK, Gordon KB. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. J Am Acad Dermatol. 2017;76(3):418\u201331. https:\/\/doi.org\/10.1016\/j.jaad.2016.11.042.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"9356_CR13","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.jaad.2016.11.042","volume":"76","author":"K Reich","year":"2017","unstructured":"Reich K, Armstrong AW, Foley P, Song M, Wasfi Y, Randazzo B, Li S, Shen YK, Gordon KB. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. J Am Acad Dermatol. 2017;76(3):418\u201331. https:\/\/doi.org\/10.1016\/j.jaad.2016.11.042.","journal-title":"J Am Acad Dermatol"},{"key":"9356_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/09546634.2019.1679336","volume":"21","author":"L Puig","year":"2019","unstructured":"Puig L, Wu JJ, Gooderham MJ, You Y, Shen YK, Randazzo B, Kerdel F. Consistent response to guselkumab treatment between Hispanic and non-Hispanic patients with psoriasis: an analysis from VOYAGE 1 and VOYAGE 2. J Dermatolog Treat. 2019;21:1\u20138. https:\/\/doi.org\/10.1080\/09546634.2019.1679336.","journal-title":"J Dermatolog Treat"},{"issue":"12","key":"9356_CR15","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1111\/1346-8138.15109","volume":"46","author":"K Reich","year":"2019","unstructured":"Reich K, Song M, Li S, Jiang J, Youn SW, Tsai TF, Choe YB, Huang YH, Gordon KB. Consistent responses with guselkumab treatment in Asian and non-Asian patients with psoriasis: an analysis from VOYAGE 1 and VOYAGE 2. J Dermatol. 2019;46(12):1141\u201352. https:\/\/doi.org\/10.1111\/1346-8138.15109.","journal-title":"J Dermatol"},{"key":"9356_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/09546634.2020.1782817","volume":"13","author":"CEM Griffiths","year":"2020","unstructured":"Griffiths CEM, Papp KA, Song M, Miller M, You Y, Shen YK, Han C, Blauvelt A. Continuous treatment with guselkumab maintains clinical responses through 4 years in patients with moderate-to-severe psoriasis: results from VOYAGE 1. J Dermatolog Treat. 2020;13:1\u20139. https:\/\/doi.org\/10.1080\/09546634.2020.1782817.","journal-title":"J Dermatolog Treat."},{"issue":"8","key":"9356_CR17","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1111\/jdv.16460","volume":"34","author":"L Puig","year":"2020","unstructured":"Puig L, Tsai TF, Bhutani T, Uy J, Ramachandran P, Song M, You Y, Gooderham M, Lebwohl M. Safety in moderate-to-severe plaque psoriasis patients with latent tuberculosis treated with guselkumab and anti-tuberculosis treatments concomitantly: results from pooled phase 3 VOYAGE 1 & VOYAGE 2 trials. J Eur Acad Dermatol Venereol. 2020;34(8):1744\u20139. https:\/\/doi.org\/10.1111\/jdv.16460.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"9356_CR18","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1016\/j.jaad.2019.11.040","volume":"82","author":"K Reich","year":"2020","unstructured":"Reich K, Griffiths CEM, Gordon KB, Papp KA, Song M, Randazzo B, Li S, Shen YK, Han C, Kimball AB, Armstrong AW, Foley P, Blauvelt A. Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: results from the VOYAGE 1 and VOYAGE 2 trials. J Am Acad Dermatol. 2020;82(4):936\u201345. https:\/\/doi.org\/10.1016\/j.jaad.2019.11.040.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"9356_CR19","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1007\/s40257-020-00555-7","volume":"21","author":"K Reich","year":"2020","unstructured":"Reich K, Armstrong AW, Foley P, Song M, Miller M, Shen YK, You Y, Han C, Gordon KB. Maintenance of response through up to 4 years of continuous guselkumab treatment of psoriasis in the VOYAGE 2 phase 3 study. Am J Clin Dermatol. 2020;21(6):881\u201390. https:\/\/doi.org\/10.1007\/s40257-020-00555-7.","journal-title":"Am J Clin Dermatol"},{"key":"9356_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/09546634.2020.1770174","volume":"27","author":"SW Youn","year":"2020","unstructured":"Youn SW, Yu DY, Kim TY, Kim BS, Lee SC, Lee JH, Choe YB, Lee JH, Choi JH, Roh JY, Jo SJ, Lee ES, Shin MK, Lee MG, Jiang J, Lee Y. Efficacy and safety of guselkumab compared with placebo and adalimumab in Korean patients with moderate-to-severe psoriasis: post-hoc analysis from the phase III, double-blind, placebo- and active-comparator-controlled VOYAGE 1\/2 trials. J Dermatolog Treat. 2020;27:1\u20137. https:\/\/doi.org\/10.1080\/09546634.2020.1770174.","journal-title":"J Dermatolog Treat"},{"issue":"10148","key":"9356_CR21","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/S0140-6736(18)31713-6","volume":"392","author":"KB Gordon","year":"2018","unstructured":"Gordon KB, Strober B, Lebwohl M, et al. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. Lancet. 2018;392(10148):650\u201361.","journal-title":"Lancet"},{"issue":"4","key":"9356_CR22","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1111\/bjd.13932","volume":"173","author":"K Papp","year":"2015","unstructured":"Papp K, Thaci D, Reich K, et al. Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improved psoriasis in a phase Iib randomized placebo-controlled trial. Br J Dermatol. 2015;173(4):930\u20139.","journal-title":"Br J Dermatol"},{"issue":"10091","key":"9356_CR23","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/S0140-6736(17)31279-5","volume":"390","author":"K Reich","year":"2017","unstructured":"Reich K, Papp KA, Blauvelt A, et al. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomized controlled phase 3 trials. Lancet. 2017;390(10091):276\u201388.","journal-title":"Lancet"},{"issue":"1","key":"9356_CR24","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1111\/bjd.15750","volume":"178","author":"RG Langley","year":"2018","unstructured":"Langley RG, Tsai TF, Flavin S, Song M, Randazzo B, Wasfi Y, Jiang J, Li S, Puig L. Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double-blind, phase III NAVIGATE trial. Br J Dermatol. 2018;178(1):114\u201323. https:\/\/doi.org\/10.1111\/bjd.15750.","journal-title":"Br J Dermatol"},{"issue":"10201","key":"9356_CR25","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/S0140-6736(19)31773-8","volume":"394","author":"K Reich","year":"2019","unstructured":"Reich K, Armstrong AW, Langley RG, Flavin S, Randazzo B, Li S, Hsu MC, Branigan P, Blauvelt A. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial. Lancet. 2019;394(10201):831\u20139. https:\/\/doi.org\/10.1016\/S0140-6736(19)31773-8.","journal-title":"Lancet"},{"issue":"6","key":"9356_CR26","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1111\/bjd.18851","volume":"182","author":"A Blauvelt","year":"2020","unstructured":"Blauvelt A, Papp K, Gottlieb A, Jarell A, Reich K, Maari C, Gordon KB, Ferris LK, Langley RG, Tada Y, Lima RG, Elmaraghy H, Gallo G, Renda L, Park SY, Burge R, Bagel J, IXORA-R Study Group. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial. Br J Dermatol. 2020;182(6):1348\u201358. https:\/\/doi.org\/10.1111\/bjd.18851.","journal-title":"Br J Dermatol"},{"key":"9356_CR27","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19509","author":"A Blauvelt","year":"2020","unstructured":"Blauvelt A, Leonardi C, Elewski B, Crowley JJ, Guenther LC, Gooderham M, Langley RG, Vender R, Pinter A, Griffiths CEM, Tada Y, Elmaraghy H, Lima RG, Gallo G, Renda L, Burge R, Park SY, Zhu B, Papp K, IXORA-R Study Group. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 24-week efficacy and safety results from a randomized, double-blinded trial. Br J Dermatol. 2020. https:\/\/doi.org\/10.1111\/bjd.19509.","journal-title":"Br J Dermatol."},{"issue":"2","key":"9356_CR28","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1111\/bjd.18696","volume":"183","author":"D Tha\u00e7i","year":"2020","unstructured":"Tha\u00e7i D, Pinter A, Sebastian M, Termeer C, Sticherling M, Gerdes S, Wegner S, Krampe S, Bartz H, Rausch C, Mensch A, Eyerich K. Guselkumab is superior to fumaric acid esters in patients with moderate-to-severe plaque psoriasis who are naive to systemic treatment: results from a randomized, active-comparator-controlled phase IIIb trial (POLARIS). Br J Dermatol. 2020;183(2):265\u201375. https:\/\/doi.org\/10.1111\/bjd.18696.","journal-title":"Br J Dermatol"},{"issue":"6","key":"9356_CR29","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1177\/1203475420932514","volume":"24","author":"K Maliyar","year":"2020","unstructured":"Maliyar K, O\u2019Toole A, Gooderham MJ. Long-term single center experience in treating plaque psoriasis with guselkumab. J Cutan Med Surg. 2020;24(6):588\u201395. https:\/\/doi.org\/10.1177\/1203475420932514.","journal-title":"J Cutan Med Surg"},{"issue":"6","key":"9356_CR30","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1016\/j.jaad.2020.04.025","volume":"83","author":"A Mufti","year":"2020","unstructured":"Mufti A, Maliyar K, Walton L, Vender R, Yeung J. Guselkumab dosing interval optimization in adult patients with psoriasis: a retrospective, multicenter case series. J Am Acad Dermatol. 2020;83(6):1813\u20134. https:\/\/doi.org\/10.1016\/j.jaad.2020.04.025.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"9356_CR31","doi-asserted-by":"publisher","first-page":"e14673","DOI":"10.1111\/dth.14673","volume":"34","author":"A Ruggiero","year":"2021","unstructured":"Ruggiero A, Fabbrocini G, Cinelli E, Megna M. Efficacy and safety of guselkumab in psoriasis patients who failed ustekinumab and\/or anti-interleukin-17 treatment: a real-life 52-week retrospective study. Dermatol Ther. 2021;34(1):e14673. https:\/\/doi.org\/10.1111\/dth.14673.","journal-title":"Dermatol Ther"},{"issue":"6","key":"9356_CR32","doi-asserted-by":"publisher","first-page":"e13964","DOI":"10.1111\/dth.13964","volume":"33","author":"I Snast","year":"2020","unstructured":"Snast I, Sherman S, Holzman R, Hodak E, Pavlovsky L. Real-life experience of guselkumab in patients with psoriasis. Dermatol Ther. 2020;33(6):e13964. https:\/\/doi.org\/10.1111\/dth.13964.","journal-title":"Dermatol Ther"},{"key":"9356_CR33","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.17092","author":"JFB Schwensen","year":"2020","unstructured":"Schwensen JFB, Nielsen VW, Nissen CV, Sand C, Gniadecki R, Thomsen SF. Effectiveness and safety of guselkumab in 50 patients with moderate to severe plaque psoriasis who had previously been treated with other biologics: a retrospective real-world evidence study. J Eur Acad Dermatol Venereol. 2020. https:\/\/doi.org\/10.1111\/jdv.17092.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"9356_CR34","doi-asserted-by":"publisher","first-page":"e14798","DOI":"10.1111\/dth.14798","volume":"34","author":"R Ruiz-Villaverde","year":"2021","unstructured":"Ruiz-Villaverde R, Rodriguez-Fernandez-Freire L, Armario-Hita JC, P\u00e9rez-Gil A, Gal\u00e1n-Guti\u00e9rrez M. Guselkumab: mid-term effectiveness, drug survival, and safety in real clinical practice. Dermatol Ther. 2021;34(2):e14798. https:\/\/doi.org\/10.1111\/dth.14798.","journal-title":"Dermatol Ther"},{"issue":"11","key":"9356_CR35","doi-asserted-by":"crossref","first-page":"13030\/qt3db748c","DOI":"10.5070\/D32411041999","volume":"24","author":"G Bartos","year":"2018","unstructured":"Bartos G, Cline A, Beroukhim K, Burrall BA, Feldman SR. Current biological therapies for use in HIV-positive patients with psoriasis: case report of gesulkumab used and review. Dermatol Online J. 2018;24(11):13030\/qt3db748cg.","journal-title":"Dermatol Online J"},{"issue":"2","key":"9356_CR36","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1080\/09546634.2019.1654067","volume":"32","author":"HS Berman","year":"2021","unstructured":"Berman HS, Villa NM, Shi VY, Hsiao JL. Guselkumab in the treatment of concomitant hidradenitis suppurativa, psoriasis, and Crohn\u2019s disease. J Dermatolog Treat. 2021;32(2):261\u20133. https:\/\/doi.org\/10.1080\/09546634.2019.1654067.","journal-title":"J Dermatolog Treat"},{"issue":"4","key":"9356_CR37","doi-asserted-by":"publisher","first-page":"e13433","DOI":"10.1111\/dth.13433","volume":"33","author":"C Mugheddu","year":"2020","unstructured":"Mugheddu C, Dell\u2019Antonia M, Sanna S, Agosta D, Atzori L, Rongioletti F. Successful guselkumab treatment in a psoriatic patient affected with Cornelia de Lange syndrome, and prosecution during the COVID-19 pandemic. Dermatol Ther. 2020;33(4):e13433. https:\/\/doi.org\/10.1111\/dth.13433.","journal-title":"Dermatol Ther"},{"issue":"1","key":"9356_CR38","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s13555-020-00480-x","volume":"11","author":"CY Chiang","year":"2021","unstructured":"Chiang CY, Tsai TF. Treatment response of patients with erythrodermic psoriasis after switching to guselkumab. Dermatol Ther (Heidelb). 2021;11(1):301\u20136. https:\/\/doi.org\/10.1007\/s13555-020-00480-x.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"21","key":"9356_CR39","doi-asserted-by":"publisher","first-page":"00170","DOI":"10.1016\/j.jaad.2021.01.025","volume":"S0190\u20139622","author":"A Ruggiero","year":"2021","unstructured":"Ruggiero A, Fabbrocini G, Cinelli E, Megna M. Guselkumab and risankizumab for psoriasis: a 44-week indirect real-life comparison. J Am Acad Dermatol. 2021;S0190\u20139622(21):00170\u20135. https:\/\/doi.org\/10.1016\/j.jaad.2021.01.025.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"9356_CR40","doi-asserted-by":"publisher","first-page":"e14814","DOI":"10.1111\/dth.14814","volume":"34","author":"C Kromer","year":"2021","unstructured":"Kromer C, Loewe E, Schaarschmidt ML, Pinter A, Gerdes S, Herr R, Poortinga S, Moessner R, Wilsmann-Theis D. Drug survival in the treatment of generalized pustular psoriasis: a retrospective multicenter study. Dermatol Ther. 2021;34(2):e14814. https:\/\/doi.org\/10.1111\/dth.14814.","journal-title":"Dermatol Ther"},{"issue":"3","key":"9356_CR41","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1001\/jamadermatol.2017.5937","volume":"154","author":"T Terui","year":"2018","unstructured":"Terui T, Kobayashi S, Okubo Y, Murakami M, Hirose K, Kubo H. Efficacy and safety of guselkumab, an anti-interleukin 23 monoclonal antibody, for palmoplantar pustulosis: a randomized clinical trial. JAMA Dermatol. 2018;154(3):309\u201316. https:\/\/doi.org\/10.1001\/jamadermatol.2017.5937.","journal-title":"JAMA Dermatol"},{"issue":"11","key":"9356_CR42","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1016\/j.jdcr.2019.09.005","volume":"5","author":"B Reyn","year":"2019","unstructured":"Reyn B, Hillary T, Gils A. Eczematous eruption after guselkumab treatment for psoriasis. JAAD Case Rep. 2019;5(11):973\u20135. https:\/\/doi.org\/10.1016\/j.jdcr.2019.09.005.","journal-title":"JAAD Case Rep"},{"issue":"4","key":"9356_CR43","doi-asserted-by":"publisher","first-page":"e12954","DOI":"10.1111\/dth.12954","volume":"32","author":"A Truong","year":"2019","unstructured":"Truong A, Le S, Kiuru M, Maverakis E. Nummular dermatitis on guselkumab for palmoplantar psoriasis. Dermatol Ther. 2019;32(4):e12954. https:\/\/doi.org\/10.1111\/dth.12954.","journal-title":"Dermatol Ther"},{"issue":"1","key":"9356_CR44","first-page":"13030\/qt0pc0g80","volume":"25","author":"EB Lee","year":"2019","unstructured":"Lee EB, Reynolds KA, Pithadia DJ, Wu JJ. Appearance of lentigines in psoriasis patient treated with guselkumab. Dermatol Online J. 2019;25(1):13030\/qt0pc0g809.","journal-title":"Dermatol Online J"},{"issue":"6","key":"9356_CR45","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1001\/jamadermatol.2018.0793","volume":"154","author":"P Foley","year":"2018","unstructured":"Foley P, Gordon K, Griffiths CEM, Wasfi Y, Randazzo B, Song M, Li S, Shen YK, Blauvelt A. Efficacy of guselkumab compared with adalimumab and placebo for psoriasis in specific body regions: a secondary analysis of 2 randomized clinical trials. JAMA Dermatol. 2018;154(6):676\u201383. https:\/\/doi.org\/10.1001\/jamadermatol.2018.0793.","journal-title":"JAMA Dermatol"},{"issue":"9","key":"9356_CR46","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1111\/1346-8138.14504","volume":"45","author":"M Ohtsuki","year":"2018","unstructured":"Ohtsuki M, Kubo H, Morishima H, Goto R, Zheng R, Nakagawa H. Guselkumab, an anti-interleukin-23 monoclonal antibody, for the treatment of moderate to severe plaque-type psoriasis in Japanese patients: efficacy and safety results from a phase 3, randomized, double-blind, placebo-controlled study. J Dermatol. 2018;45(9):1053\u201362. https:\/\/doi.org\/10.1111\/1346-8138.14504.","journal-title":"J Dermatol"},{"issue":"5","key":"9356_CR47","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1111\/1346-8138.14294","volume":"45","author":"S Sano","year":"2018","unstructured":"Sano S, Kubo H, Morishima H, Goto R, Zheng R, Nakagawa H. Guselkumab, a human interleukin-23 monoclonal antibody in Japanese patients with generalized pustular psoriasis and erythrodermic psoriasis: efficacy and safety analyses of a 52-week, phase 3, multicenter, open-label study. J Dermatol. 2018;45(5):529\u201339. https:\/\/doi.org\/10.1111\/1346-8138.14294.","journal-title":"J Dermatol"},{"issue":"2","key":"9356_CR48","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1080\/09546634.2019.1587145","volume":"31","author":"LK Ferris","year":"2020","unstructured":"Ferris LK, Ott E, Jiang J, Hong HC, Li S, Han C, Baran W. Efficacy and safety of guselkumab, administered with a novel patient-controlled injector (One-Press), for moderate-to-severe psoriasis: results from the phase 3 ORION study. J Dermatolog Treat. 2020;31(2):152\u20139. https:\/\/doi.org\/10.1080\/09546634.2019.1587145.","journal-title":"J Dermatolog Treat"},{"issue":"12","key":"9356_CR49","doi-asserted-by":"publisher","first-page":"e837","DOI":"10.1111\/jdv.16715","volume":"34","author":"F Benhadou","year":"2020","unstructured":"Benhadou F, Ghislain PD, Guiot F, Willaert F, Del Marmol V, Lambert J, Soenen R, Fierens H, de la Brassinne M. Real-life effectiveness and short-term (16-week) tolerance of guselkumab for psoriasis: a Belgian retrospective multicentre study. J Eur Acad Dermatol Venereol. 2020;34(12):e837\u20139. https:\/\/doi.org\/10.1111\/jdv.16715.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"7","key":"9356_CR50","doi-asserted-by":"publisher","first-page":"2170","DOI":"10.3390\/jcm9072170","volume":"9","author":"M Galluzzo","year":"2020","unstructured":"Galluzzo M, Tofani L, Lombardo P, Petruzzellis A, Silvaggio D, Egan CG, Bianchi L, Talamonti M. Use of guselkumab for the treatment of moderate-to-severe plaque psoriasis: a 1 year real-life study. J Clin Med. 2020;9(7):2170. https:\/\/doi.org\/10.3390\/jcm9072170.","journal-title":"J Clin Med"},{"issue":"4","key":"9356_CR51","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1080\/09546634.2019.1605133","volume":"31","author":"EB Lee","year":"2020","unstructured":"Lee EB, Reynolds KA, Pithadia DJ, Egeberg A, Wu JJ. Drug survival of guselkumab for psoriasis in a real-world setting: a single-center retrospective chart review. J Dermatolog Treat. 2020;31(4):342\u20133. https:\/\/doi.org\/10.1080\/09546634.2019.1605133.","journal-title":"J Dermatolog Treat"},{"key":"9356_CR52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/09546634.2020.1800577","volume":"4","author":"M Megna","year":"2020","unstructured":"Megna M, Fabbrocini G, Cinelli E, Camela E, Ruggiero A. Guselkumab in moderate to severe psoriasis in routine clinical care: an Italian 44-week real-life experience. J Dermatolog Treat. 2020;4:1\u20135. https:\/\/doi.org\/10.1080\/09546634.2020.1800577.","journal-title":"J Dermatolog Treat"},{"issue":"9","key":"9356_CR53","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1111\/1346-8138.15466","volume":"47","author":"C Kromer","year":"2020","unstructured":"Kromer C, Loewe E, Schaarschmidt ML, Pinter A, Gerdes S, Celis D, Poortinga S, Wilsmann-Theis D, M\u00f6ssner R. Treatment of acrodermatitis continua of Hallopeau: a case series of 39 patients. J Dermatol. 2020;47(9):989\u201397. https:\/\/doi.org\/10.1111\/1346-8138.15466.","journal-title":"J Dermatol"},{"issue":"7","key":"9356_CR54","doi-asserted-by":"publisher","first-page":"e84","DOI":"10.1093\/ibd\/izz033","volume":"25","author":"LB Grossberg","year":"2019","unstructured":"Grossberg LB. A case report of successful treatment of Crohn\u2019s disease and psoriasis with guselkumab. Inflamm Bowel Dis. 2019;25(7):e84. https:\/\/doi.org\/10.1093\/ibd\/izz033.","journal-title":"Inflamm Bowel Dis"},{"issue":"8","key":"9356_CR55","first-page":"822","volume":"18","author":"SL Hall","year":"2019","unstructured":"Hall SL, Haidari W, Feldman SR. Resolution of guttate psoriasis plaques after one-time administration of guselkumab. J Drugs Dermatol. 2019;18(8):822\u20133.","journal-title":"J Drugs Dermatol"},{"issue":"8","key":"9356_CR56","doi-asserted-by":"publisher","first-page":"e302","DOI":"10.1111\/1346-8138.14842","volume":"46","author":"Y Hosokawa","year":"2019","unstructured":"Hosokawa Y, Hamada T, Ashida H, Ikeda M. Effective treatment with guselkumab for psoriatic alopecia as paradoxical reaction. J Dermatol. 2019;46(8):e302\u20133. https:\/\/doi.org\/10.1111\/1346-8138.14842.","journal-title":"J Dermatol"},{"issue":"6","key":"9356_CR57","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.jdcr.2019.04.014","volume":"5","author":"SR Kim","year":"2019","unstructured":"Kim SR, Kibbi N, Craiglow BG. Guselkumab for the treatment of severe refractory psoriasis in a pediatric patient. JAAD Case Rep. 2019;5(6):552\u20134. https:\/\/doi.org\/10.1016\/j.jdcr.2019.04.014.","journal-title":"JAAD Case Rep"},{"issue":"4","key":"9356_CR58","first-page":"394","volume":"18","author":"D Rathod","year":"2019","unstructured":"Rathod D, Weinberg JM, Yamauchi PS, Kircik LH, Wollina U, Lotti T, Goldust M. Successful treatment of refractory plaque-type psoriasis and psoriatic arthritis with guselkumab and adalimumab combination therapy: a case report. J Drugs Dermatol. 2019;18(4):394\u20136.","journal-title":"J Drugs Dermatol"},{"issue":"5","key":"9356_CR59","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1684\/ejd.2020.3860","volume":"30","author":"K Kamiya","year":"2020","unstructured":"Kamiya K, Yamauchi H, Ohtsuki M. Treatment of psoriasis vulgaris with guselkumab in a patient with non-small cell lung cancer. Eur J Dermatol. 2020;30(5):609\u201311. https:\/\/doi.org\/10.1684\/ejd.2020.3860.","journal-title":"Eur J Dermatol"},{"issue":"2","key":"9356_CR60","doi-asserted-by":"publisher","first-page":"e13238","DOI":"10.1111\/dth.13238","volume":"33","author":"M Megna","year":"2020","unstructured":"Megna M, Ruggiero A, Camela E, Fabbrocini G, Marasca C. A case of erythrodermic psoriasis successfully treated with guselkumab. Dermatol Ther. 2020;33(2):e13238. https:\/\/doi.org\/10.1111\/dth.13238.","journal-title":"Dermatol Ther"},{"issue":"8","key":"9356_CR61","first-page":"37","volume":"14","author":"EJ Song","year":"2020","unstructured":"Song EJ, Whitman P, Samsel J. The use of ustekinumab and guselkumab in a pediatric psoriasis patient with active hepatitis B infection. JAAD Case Rep. 2020;14(8):37\u20139.","journal-title":"JAAD Case Rep"},{"issue":"16","key":"9356_CR62","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1056\/NEJMoa1607017","volume":"376","author":"KA Papp","year":"2017","unstructured":"Papp KA, Blauvelt A, Bukhalo M, et al. Risankizumab versus ustekinumab for moderate-to-severe plaque psoriasis. N Engl J Med. 2017;376(16):1551\u201360.","journal-title":"N Engl J Med"},{"issue":"6","key":"9356_CR63","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1001\/jamadermatol.2020.0723","volume":"156","author":"A Blauvelt","year":"2020","unstructured":"Blauvelt A, Leonardi CL, Gooderham M, et al. Efficacy and safety of continuous risankizumab therapy vs treatment withdrawal in patients with moderate to severe plaque psoriasis: a phase 3 randomized clinical trial. JAMA Dermatol. 2020;156(6):649\u201358.","journal-title":"JAMA Dermatol"},{"issue":"10198","key":"9356_CR64","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/S0140-6736(19)30952-3","volume":"394","author":"K Reich","year":"2019","unstructured":"Reich K, Gooderham M, Tha\u00e7i D, et al. Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial. Lancet. 2019;394(10198):576\u201386.","journal-title":"Lancet"},{"issue":"1","key":"9356_CR65","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1111\/bjd.19341","volume":"184","author":"RB Warren","year":"2021","unstructured":"Warren RB, Blauvelt A, Poulin Y, et al. Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): results from a phase III, randomized, open-label, efficacy-assessor-blinded clinical trial. Br J Dermatol. 2021;184(1):50\u20139.","journal-title":"Br J Dermatol"},{"key":"9356_CR66","unstructured":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2016-003718-28\/results, Accessed 19\u00a0April\u00a02021."},{"issue":"3","key":"9356_CR67","doi-asserted-by":"publisher","first-page":"e169","DOI":"10.1111\/jdv.17003","volume":"35","author":"K Hansel","year":"2021","unstructured":"Hansel K, Zangrilli A, Bianchi L, et al. A multicenter study on effectiveness and safety of risankizumab in psoriasis: an Italian 16-week real-life experience during the COVID-19 pandemic. J Eur Acad Dermatol Venereol. 2021;35(3):e169\u201370.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"9356_CR68","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1111\/bjd.19575","volume":"184","author":"R Reddy","year":"2021","unstructured":"Reddy R, Pannu S, Fiumara K, et al. Efficacy of in-class interleukin-23 inhibitor switching: risankizumab following guselkumab failure in moderate-to-severe psoriasis treatment. Br J Dermatol. 2021;184(3):559\u201361.","journal-title":"Br J Dermatol"},{"issue":"6","key":"9356_CR69","doi-asserted-by":"publisher","first-page":"e14144","DOI":"10.1111\/dth.14144","volume":"33","author":"M Megna","year":"2020","unstructured":"Megna M, Fabbrocini G, Ruggiero A, et al. Efficacy and safety of risankizumab in psoriasis patients who failed anti-IL-17, anti-12\/23 and\/or anti IL-23: preliminary data of a real-life 16-week retrospective study. Dermatol Ther. 2020;33(6):e14144.","journal-title":"Dermatol Ther"},{"issue":"3","key":"9356_CR70","doi-asserted-by":"publisher","first-page":"e124","DOI":"10.1111\/1346-8138.15726","volume":"48","author":"Y Tsuchida","year":"2021","unstructured":"Tsuchida Y, Fujimoto A, Shigehara Y, et al. Risankizumab for treating chronic plaque psoriasis complicated by recurrent diverticulitis: a case report. J Dermatol. 2021;48(3):e124-125.","journal-title":"J Dermatol"},{"key":"9356_CR71","unstructured":"https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02513459?term=risankizumab&cond=inflammatory+bowel+disease&draw=2&rank=1,\u00a0 Accessed 19\u00a0April\u00a02021."},{"issue":"2","key":"9356_CR72","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s13555-021-00490-3","volume":"11","author":"KA Papp","year":"2021","unstructured":"Papp KA, de Vente S, Zeng J, et al. Long-term safety and efficacy of risankizumab in patients with moderate-to-severe chronic plaque psoriasis: results from a phase 2 open-label extension trial. Dermatol Ther (Heidelb). 2021;11(2):487\u201397.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"9356_CR73","doi-asserted-by":"publisher","unstructured":"Megna M, Cinelli E, Gallo L, Camela E, Ruggiero A, Fabbrocini G. Risankizumab in real life: preliminary results of efficacy and safety in psoriasis during a 16-week period.\u00a0Arch Dermatol Res. 2022;314(6):619\u2013623.\u00a0https:\/\/doi.org\/10.1007\/s00403-021-02200-7","DOI":"10.1007\/s00403-021-02200-7"},{"issue":"8","key":"9356_CR74","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1111\/1346-8138.14941","volume":"46","author":"M Ohtsuki","year":"2019","unstructured":"Ohtsuki M, Fujita H, Watanabe M, Suzaki K, Flack M, Huang X, Kitamura S, Valdes J, Igarashi A. Efficacy and safety of risankizumab in Japanese patients with moderate to severe plaque psoriasis: results from the SustaIMM phase 2\/3 trial. J Dermatol. 2019;46(8):686\u201394.","journal-title":"J Dermatol"},{"key":"9356_CR75","first-page":"e14584","volume":"25","author":"C Bonifati","year":"2020","unstructured":"Bonifati C, Morrone A, Cristaudo A, et al. Effectiveness of anti-interleukin 23 biologic drugs in psoriasis patients who failed anti-interleukin 17 regimens. A real-life experience. Dermatol Ther. 2020;25:e14584.","journal-title":"Dermatol Ther"},{"issue":"6","key":"9356_CR76","doi-asserted-by":"publisher","first-page":"e14374","DOI":"10.1111\/dth.14374","volume":"33","author":"C Kromer","year":"2020","unstructured":"Kromer C, Mohr J, Sch\u00f6n MP, et al. Successful therapy of psoriasis with risankizumab after previous failure of guselkumab and tildrakizumab. Dermatol Ther. 2020;33(6):e14374.","journal-title":"Dermatol Ther"},{"issue":"3","key":"9356_CR77","doi-asserted-by":"publisher","first-page":"e13323","DOI":"10.1111\/dth.13323","volume":"33","author":"R Ruiz-Villaverde","year":"2020","unstructured":"Ruiz-Villaverde R, Ay\u00e9n-Rodriguez A, Llamas-Molina JM, et al. Risankizumab as a promising therapeutic approach in obese patients. Dermatol Ther. 2020;33(3):e13323.","journal-title":"Dermatol Ther"},{"issue":"3","key":"9356_CR78","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1111\/bjd.18232","volume":"182","author":"K Reich","year":"2020","unstructured":"Reich K, Warren RB, Iversen L, et al. Long\u2014term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis:pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeks. Br J Dermatol. 2020;182(3):605\u201317.","journal-title":"Br J Dermatol"},{"key":"9356_CR79","unstructured":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03718299, Accessed 19\u00a0April\u00a02021."},{"key":"9356_CR80","unstructured":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04823247, Accessed 19\u00a0April\u00a02021."},{"issue":"6","key":"9356_CR81","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1111\/jdv.15400","volume":"33","author":"KA Papp","year":"2019","unstructured":"Papp KA, Reich K, Blauvelt A, et al. Efficacy of tildrakizumab for moderate-to-severe plaque psoriasis: pooles analysis of three randomized controlled trials at week 12 and 28. J Eur Acad Dermatol Venereol. 2019;33(6):1098\u2013106.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"8","key":"9356_CR82","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1080\/09546634.2019.1640348","volume":"31","author":"B Elewski","year":"2020","unstructured":"Elewski B, Menter A, Crowley J, et al. Sustained and continuously improved efficacy of tildrakizumab in patients with moderate-to-severe plaque psoriasis. J Dermatolog Treat. 2020;31(8):763\u20138.","journal-title":"J Dermatolog Treat"},{"issue":"6","key":"9356_CR83","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1111\/bjd.18484","volume":"182","author":"AB Kimball","year":"2020","unstructured":"Kimball AB, Papp KA, Reich K, et al. Efficacy and safety of tildrakizumab for plaque psoriasis with continous dosing, treatment interruption, dose adjustments and switching from etanercept: results from phase III studies. Br J Dermatol. 2020;182(6):1359\u201368.","journal-title":"Br J Dermatol"},{"issue":"12","key":"9356_CR84","doi-asserted-by":"publisher","first-page":"e803","DOI":"10.1111\/jdv.16648","volume":"34","author":"MA Menter","year":"2020","unstructured":"Menter MA, Murakawa GJ, Glover H, et al. Clearance of head and neck involvement in plaque psoriasis with tildrakizumab treatment in the phase 3 reSURFACE 1 study. J Eur Acad Dermatol Venereol. 2020;34(12):e803\u20135.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"9356_CR85","doi-asserted-by":"publisher","unstructured":"Gordon KB, Reich K, Crowley JJ, et al. Disease activity and treatment efficacy using patient-level psoriasis area and severity index scores from tildrakizumab phase 3 clinical trials. J Dermatolog Treat. 2022;33(1):219\u2013228.\u00a0https:\/\/doi.org\/10.1080\/09546634.2020.1747590","DOI":"10.1080\/09546634.2020.1747590"},{"key":"9356_CR86","doi-asserted-by":"publisher","unstructured":"Imafuku S, Nakagawa H, Igarashi A, et al. Long-term efficacy and safety of tildrakizumab in Japanese patients with moderate to severe plaque psoriasis: results from a 5-year extension of a phase 3 study (reSURFACE 1). J Dermatol.\u00a02021;48(6):844\u2013852. https:\/\/doi.org\/10.1111\/1346-8138.15763. Online ahead of print.","DOI":"10.1111\/1346-8138.15763"},{"key":"9356_CR87","doi-asserted-by":"publisher","unstructured":"Cantrell W, Lee P, Mendelsohn AM, et al. Efficacy and safety of tildrakizumab 100 mg for plaque psoriasis in patients randomised to treatment continuation vs. treatment withdrawl with retreatment upon relapse in reSURFACE 1. J Eur Acad Dermatol Venereol. 2021;35(8):e526\u2013e528. https:\/\/doi.org\/10.1111\/jdv.17124. Online ahead of print.","DOI":"10.1111\/jdv.17124"},{"issue":"2","key":"9356_CR88","doi-asserted-by":"publisher","first-page":"e14857","DOI":"10.1111\/dth.14857","volume":"34","author":"E Camela","year":"2021","unstructured":"Camela E, Ocampo-Garza SS, Cinelli E, et al. Therapeutic update of biologics and small molecules for scalp psoriasis: a systematic review. Dermatol Ther. 2021;34(2):e14857.","journal-title":"Dermatol Ther"},{"key":"9356_CR89","doi-asserted-by":"publisher","unstructured":"Cinelli E, Fabbrocini G, Megna M. Real-world experience versus clinical trials: pros and cons in psoriasis therapy evaluation. Int J Dermatol. 2022;61(3):e107-e108.\u00a0https:\/\/doi.org\/10.1111\/ijd.15644.","DOI":"10.1111\/ijd.15644"},{"issue":"3","key":"9356_CR90","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1111\/ced.14979","volume":"47","author":"A Ruggiero","year":"2022","unstructured":"Ruggiero A, Fabbrocini G, Cinelli E, Ocampo Garza SS, Camela E, Megna M. Anti-interleukin-23 for psoriasis in elderly patients: guselkumab, risankizumab and tildrakizumab in real-world practice. Clin Exp Dermatol. 2022;47(3):561\u20137.","journal-title":"Clin Exp Dermatol"},{"issue":"1","key":"9356_CR91","doi-asserted-by":"publisher","first-page":"e11","DOI":"10.1111\/jdv.17665","volume":"36","author":"M Megna","year":"2022","unstructured":"Megna M, Potestio L, Gallo L, Caiazzo G, Ruggiero A, Fabbrocini G. Reply to \u201cPsoriasis exacerbation after COVID-19 vaccination: report of 14 cases from a single centre\u201d by Sotiriou E et al. J Eur Acad Dermatol Venereol. 2022;36(1):e11\u20133.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"9356_CR92","doi-asserted-by":"publisher","first-page":"109853","DOI":"10.1016\/j.mehy.2020.109853","volume":"143","author":"C Marasca","year":"2020","unstructured":"Marasca C, Ruggiero A, Napolitano M, Fabbrocini G, Megna M. May COVID-19 outbreaks lead to a worsening of skin chronic inflammatory conditions? Med Hypotheses. 2020;143:109853.","journal-title":"Med Hypotheses"},{"issue":"11","key":"9356_CR93","doi-asserted-by":"publisher","first-page":"e863","DOI":"10.1111\/jdv.18341","volume":"36","author":"L Potestio","year":"2022","unstructured":"Potestio L, Genco L, Villani A, et al. Reply to \u2018Cutaneous adverse effects of the available COVID-19 vaccines in India: A questionnaire-based study\u2019 by Bawane J et al. J Eur Acad Dermatol Venereol. 2022;36(11):e863\u20134.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"9356_CR94","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1080\/09546634.2020.1771257","volume":"33","author":"M Napolitano","year":"2022","unstructured":"Napolitano M, Patruno C, Ruggiero A, Nocerino M, Fabbrocini G. Safety of dupilumab in atopic patients during COVID-19 outbreak. J Dermatolog Treat. 2022;33(1):600\u20131.","journal-title":"J Dermatolog Treat"},{"issue":"1","key":"9356_CR95","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1080\/09546634.2020.1769828","volume":"33","author":"C Marasca","year":"2022","unstructured":"Marasca C, Ruggiero A, Megna M, Annunziata MC, Fabbrocini G. Biologics for patients affected by hidradenitis suppurativa in the COVID-19 era: data from a referral center of Southern Italy. J Dermatolog Treat. 2022;33(1):592.","journal-title":"J Dermatolog Treat"},{"key":"9356_CR96","doi-asserted-by":"publisher","unstructured":"Yamanaka K, Yamamoto O, Honda T. Pathophysiology of psoriasis: a review. J Dermatol. 2021 Apr 22. https:\/\/doi.org\/10.1111\/1346-8138.15913. Epub ahead of print. PMID: 33886133.","DOI":"10.1111\/1346-8138.15913"},{"issue":"5","key":"9356_CR97","doi-asserted-by":"publisher","first-page":"e15374","DOI":"10.1111\/dth.15374","volume":"35","author":"O Zagaria","year":"2022","unstructured":"Zagaria O, Villani A, Ruggiero A, Potestio L, Fabbrocini G, Gallo L. New-onset lichen planus arising after COVID-19 vaccination. Dermatol Ther. 2022;35(5):e15374.","journal-title":"Dermatol Ther"},{"issue":"3","key":"9356_CR98","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1111\/bjd.17779","volume":"181","author":"M Napolitano","year":"2019","unstructured":"Napolitano M, Megna M, Fabbrocini G, Nistic\u00f2 SP, Balato N, Dastoli S, Patruno C. Eczematous eruption during anti-interleukin 17 treatment of psoriasis: an emerging condition. Br J Dermatol. 2019;181(3):604\u20136.","journal-title":"Br J Dermatol"},{"issue":"1","key":"9356_CR99","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.clindermatol.2020.12.012","volume":"39","author":"A Patsatsi","year":"2021","unstructured":"Patsatsi A, Kyriakou A. Impact of the COVID-19 pandemic on the course and management of chronic inflammatory immune-mediated skin diseases: what\u2019s the evidence? Clin Dermatol. 2021;39(1):52\u20135.","journal-title":"Clin Dermatol"},{"key":"9356_CR100","doi-asserted-by":"publisher","DOI":"10.1684\/ejd.2021.4016","author":"N Ninosu","year":"2021","unstructured":"Ninosu N, Roehrich F, Diehl K, Peitsch WK, Schaarschmidt ML. Psoriasis care during the time of COVID-19: real-world data on changes in treatments and appointments from a German university hospital. Eur J Dermatol. 2021. https:\/\/doi.org\/10.1684\/ejd.2021.4016.","journal-title":"Eur J Dermatol"},{"issue":"11","key":"9356_CR101","doi-asserted-by":"publisher","first-page":"e680","DOI":"10.1111\/jdv.16769","volume":"34","author":"MC Annunziata","year":"2020","unstructured":"Annunziata MC, Patr\u00ec A, Ruggiero A, et al. Cutaneous involvement during COVID-19 pandemic: an emerging sign of infection. J Eur Acad Dermatol Venereol. 2020;34(11):e680\u20132.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"9356_CR102","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.jdcr.2022.03.008","volume":"23","author":"F Martora","year":"2022","unstructured":"Martora F, Picone V, Fabbrocini G, Marasca C. Hidradenitis suppurativa flares following COVID-19 vaccination: a case series. JAAD Case Rep. 2022;23:42\u20135.","journal-title":"JAAD Case Rep"},{"issue":"1","key":"9356_CR103","doi-asserted-by":"publisher","first-page":"e15197","DOI":"10.1111\/dth.15197","volume":"35","author":"V Picone","year":"2022","unstructured":"Picone V, Martora F, Fabbrocini G, Marano L. \u201cCovid arm\u201d: abnormal side effect after Moderna COVID-19 vaccine. Dermatol Ther. 2022;35(1):e15197.","journal-title":"Dermatol Ther"},{"issue":"6","key":"9356_CR104","doi-asserted-by":"publisher","first-page":"2813","DOI":"10.1080\/09546634.2022.2081655","volume":"33","author":"M Megna","year":"2022","unstructured":"Megna M, Tommasino N, Potestio L, et al. Real-world practice indirect comparison between guselkumab, risankizumab, and tildrakizumab: results from an Italian 28-week retrospective study. J Dermatolog Treat. 2022;33(6):2813\u201320.","journal-title":"J Dermatolog Treat"},{"issue":"7","key":"9356_CR105","doi-asserted-by":"publisher","first-page":"e543","DOI":"10.1111\/jdv.18017","volume":"36","author":"F Martora","year":"2022","unstructured":"Martora F, Villani A, Ocampo-Garza SS, Fabbrocini G, Megna M. Alopecia universalis improvement following risankizumab in a psoriasis patient. J Eur Acad Dermatol Venereol. 2022;36(7):e543\u20135.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"9356_CR106","doi-asserted-by":"publisher","first-page":"2813","DOI":"10.1080\/09546634.2022.2081655","volume":"33","author":"M Megna","year":"2022","unstructured":"Megna M, Tommasino N, Potestio L, et al. Real-world practice indirect comparison between guselkumab, risankizumab, and tildrakizumab: results from an Italian 28-week retrospective study. J Dermatolog Treat. 2022;33(6):2813\u201320.","journal-title":"J Dermatolog Treat"},{"issue":"4","key":"9356_CR107","doi-asserted-by":"publisher","first-page":"e13800","DOI":"10.1111\/dth.13800","volume":"33","author":"S Salimi","year":"2020","unstructured":"Salimi S, Yamauchi PS, Thakur R, Weinberg JM, Kircik L, Abdelmaksoud A, Wollina U, Lotti T, Sharma A, Grabbe S, Goldust M. Interleukin 23p19 inhibitors in chronic plaque psoriasis with focus on mirikizumab: a narrative review. Dermatol Ther. 2020;33(4):e13800.","journal-title":"Dermatol Ther"},{"issue":"4","key":"9356_CR108","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/14712598.2020.1697227","volume":"20","author":"J Han\u017eel","year":"2020","unstructured":"Han\u017eel J, D\u2019Haens GR. Anti-interleukin-23 agents for the treatment of ulcerative colitis. Expert Opin Biol Ther. 2020;20(4):399\u2013406. https:\/\/doi.org\/10.1080\/14712598.2020.1697227.","journal-title":"Expert Opin Biol Ther"}],"container-title":["Immunologic Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12026-022-09356-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12026-022-09356-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12026-022-09356-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T00:27:43Z","timestamp":1744158463000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12026-022-09356-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,4]]},"references-count":108,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["9356"],"URL":"https:\/\/doi.org\/10.1007\/s12026-022-09356-y","relation":{},"ISSN":["0257-277X","1559-0755"],"issn-type":[{"value":"0257-277X","type":"print"},{"value":"1559-0755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,4]]},"assertion":[{"value":"25 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not require.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Doctor Matteo Megna acted as speaker or consultant for Novartis, Eli Lilly, and Abbvie. Doctor Angelo Ruggiero has no conflict of interest to declare. Professor Gabriella Fabbrocini acted as speaker or consultant for Janssen, Leo Pharma, Novartis, Eli Lilly, Abbvie, and Almirall. Doctor Sonia Sof\u00eda Ocampo-Garza has no conflict of interest to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}